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Abstract
Background: Adjuvant therapy may cause multiple sideeffects on long term health, including reduced
cardiorespiratory fitness (CRF) in patients with breast cancer (1, 2). However, there is currently limited knowledge
regarding the effect of different types of adjuvant cancer treatment on CRF in other cancer populations. The
primary objective of the present study was to assess whether previously known correlates (age, diagnosis, initial
CRF, physical activity level), type of adjuvant treatment and cancer-related fatigue were associated with changes in
V̇O2 max in patients with breast, prostate or colorectal cancer.
Methods: Prospective study with two time points of assessment, 85 patients scheduled for adjuvant cancer
treatment were included. Cardiorespiratory fitness was assessed by V̇O2 max during a maximal incremental exercise
test on a treadmill before start of adjuvant therapy and again six months later. Physical activity level was recorded
with a physical activity monitor (Sense Wear™ Mini) at baseline as average minutes of moderate-to-vigorous
intensity physical activity (MVPA) per day. Physical fatigue at baseline was reported using the Multidimensional
Fatigue Inventory-20 questionaire.
Results: In multivariate linear regression analysis, 30 min higher daily MVPA at baseline was associated with a 5%
higher V̇O2 max at six months follow up when adjusted for adjuvant treatment (P = 0.010). Patients receiving
adjuvant chemotherapy had a mean decline in V̇O2 max of 10% (− 19, − 1; 95% confidence interval) compared to
patients receiving adjuvant endocrine treatment (P = 0.028). Adjuvant radiotherapy, fatigue, age and diagnosis were
not significantly associated with changes in V̇O2 max.
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Conclusion: The results of the present study indicate that adjuvant chemotherapy is associated with a subsequent
reduction in V̇O2 max in patients with cancer whereas MVPA before start of adjuvant treatment is positively
associated with a higher V̇O2 max after end of adjuvant treatment.
Keywords: Cardiopulmonary exercise testing, Physical activity, Oncological treatment, Cancer related fatigue
Background
Althought cancer treatments have documented effects
on survival, they can be invasive and toxic and cause
multiple potential negative sideeffects on long term
health including reduced physical functioning, impaired
quality of life, chronic fatigue and reduced cardiorespira-
tory fitness (CRF) [1, 2].
CRF, assessed by measurement of the maximal oxygen
uptake ( V̇O2 maxÞ; quantifies an individual’s maximal
aerobic power and provides valuable diagnostic and
prognostic information about cardiovascular function,
cardiopulmonary reserve, and efficiency of oxygen trans-
port and utilization and can disclose compensatory
mechanisms of abnormal cardiac function [3]. Previous
studies have shown that CRF in patients with cancer is
around 30% lower compared to healthy age- and sex-
matched people [4–6]. In a recent meta-analysis it is im-
plied that CRF in patients with breast cancer decreases
with approximately 10% during cancer treatment and
that reduced CRF can be measured even seven years
after end of chemotherapy treatment [7]. These findings
are of major concern given that low CRF is an important
risk factor for cardiopulmonary disease and mortality in
both healthy individuals and patients with cancer [8, 9].
Sufficient V̇O2 max is related to fewer toxic effects of
radiotherapy, chemotherapy, and endocrine therapy on
the cardiovascular system, respiratory system, and
skeletal muscles [10–15], and higher physical activity
level and daily functioning in patients with cancer [16].
Physical activity (PA) is recommended as a strategy
both during and after adjuvant treatment to manage
treatment-related symptoms, prevent early and late co-
morbidities and improve quality of life [17, 18]. Studies
has shown that physical activity, especially structured
training programs, can contribute to increase or main-
tain CRF, increase muscle strength, and improve cancer
related fatigue [18, 19]. Cancer related fatigue is a com-
mon adverse effect reported in up to 99% of all cancer
patients receiving adjuvant treatment in the form of ra-
diation therapy, chemotherapy or/and biological therapy
[20]. Cancer related fatigue causes a sense of physical,
emotional and/or cognitive tiredness in patients which is
not proportional to recent activity, and interferes with
patients usual functioning [21]. Unfortunately, studies
including self-reports of PA levels among patients with
cancer, have shown that patients reduce their PA levels
from prior to diagnosis to start of adjuvant treatment
[22], and that PA levels decrease significantly during ad-
juvant therapy [16]. In addition, similar to healthy adults,
patients with cancer are subject to the effects of ageing
and age-related deconditioning that adversely affect
components of the oxygen cascade and lead to reduced
tolerance for exercise [13]. However, in patients with
cancer, these consequences are compounded by the
effects of cancer therapies leading to reductions in exer-
cise tolerance [13].
Despite evidence that low CRF is a sign of poor prog-
nosis for cardiopulmonary disease and mortality in both
healthy individuals and patients with cancer [8, 9], there
is currently little known regarding the effect of different
types of adjuvant cancer treatment on V̇O2 max in
different cancer populations. Furthermore, the existing
literature has several important methodological limita-
tions like inconsistent assessment of physical activity
across studies, prediction or determination of cardiore-
spiratory fitness from submaximal exercise tests, and
incomplete consideration of variation of effects across
population subgroups (for example, defined by BMI, age
or sex), and sufficient considerations to other factors
that may explain study results. Knowing the effect of
different types of adjuvant cancer therapy on CRF is
important to elucidate therapy-related decrements in
CRF and for preventing further impairment.
Important clinical implications can arise from asses-
sing CRF in patients with cancer, and identifying corre-
lates associated with change in CRF. Along with data
from the Phys-Can randomized-controlled trial study
[23], knowledge from this study may also help to im-
prove the specificity of exercise prescriptions to different
patients with cancer based on their treatment regime.
The overall long term goal would be to use this know-
ledge to individualize and optimize physical activity
recommendations in order to maintain V̇O2 max during
the adjuvant phase of cancer treatment.
The primary objective of the present study was to
identify correlates of changes in V̇O2 max in patients
undergoing adjuvant treatment for breast, prostate or
colorectal cancer. More specifically, we aimed to assess
whether previously described correlates (age, diagnosis,
initial CRF, physical activity level), type of adjuvant
Wiestad et al. BMC Sports Science, Medicine and Rehabilitation           (2020) 12:53 Page 2 of 10
treatment and cancer-related fatigue were associated
with changes in V̇O2 max in patients with breast,
prostate or colorectal cancer.
Methods
Study design
The present study was a multi-center, prospective,
observational cohort study investigating changes in
cardiorespiratory fitness in patients undergoing adju-
vant treatment for cancer without any specific exercise
intervention; “The Phys-Can (Physical training and
Cancer) observational study”. The included patients
were intended to act as controls to those patients later
recruited to the Phys-Can randomized controlled
intervention study. Phys-Can has previously been de-
scribed in detail [23]. Participants in the observational
study received care as usual, including advice about
being physically active during treatment, but were not
offered to participate in an exercise intervention.
Patients aged ≥18, recently diagnosed with breast
cancer, colorectal cancer or prostate cancer, scheduled
for neoadjuvant chemotherapy (breast cancer) or
endocrine therapy (prostate cancer), and/or adjuvant
chemotherapy (breast- and colorectal cancer), adjuvant
radiotherapy (breast cancer), and/or adjuvant endo-
crine therapy (breast and prostate cancer) or radiother-
apy with curative intent without additional endocrine
therapy (prostate cancer) were recruited before start of
neoadjuvant/adjuvant cancer treatment. Patients who
were unable to understand or express themselves in
Swedish, unable to perform basic activities of daily
living, showed cognitive disorders or severe emotional
instability, or were suffering from other disabling
comorbidity that might hamper physical exercise (e.g.
unstable angina, severe heart failure, severe chronic
obstructive pulmonary disease, orthopedic conditions
and neurological disorders) were excluded from the
study. In addition patients with breast cancer stage
IIIb, men with breast cancer and patients undergoing
treatment for other types of malignant disease were
excluded from the study.
All patients were assessed by an oncologist or
surgeon regarding eligibility to participate in the study.
Patients received detailed information both written
and verbally, were given ample time to consider their
participation and written informed consent was ob-
tained from each participant before entering the study.
All tests were conducted before start of adjuvant
therapy and again six months after baseline testing.
Information on sociodemographic data were collected
at baseline only.
The Phys-Can study was registered in ClinicalTrials.gov
(TRN=NCT02473003, Oct, 2014).
Part of this study has been presented at The Annual
Congress of the EUROPEAN COLLEGE OF SPORT
SCIENCE, Prague, 2015 [24].
Participants
Participants were recruited at the University Hospitals in
Lund, Linköping and Uppsala in Sweden between
September 2014 and March 2015.
Of a total of 237 patients screened, 227 were eligible
for the study. Of these, 124 declined participation of
various reasons, and 103 accepted participation. One
participant dropped out during the inclusion process
and another was excluded due to cardiotoxicity, leaving
the total number included to 101 participants recently
diagnosed with breast (n = 85), prostate (n = 12) or
colorectal cancer (n = 4) (Fig. 1). Of the 101 patients
included, 85 (84%) completed baseline testing and 55
(54%) completed follow-up testing. Only participants
with V̇O2 max data at both baseline and post-test were
included in the final analysis.
Measures and procedures
Dependent variable
Cardiorespiratory fitness was assessed by maximal
oxygen uptake ( V̇O2 max ) during an incremental
maximal exercise test on a treadmill (Uppsala; Sports
Art Fitness, TR33, Tainan, Taiwan, Linköping; GE
Healthcare, T2100, USA, Lund; Rodby Innovation,
RL2500E, Vänge, Sweden) according to a modified
Balke protocol [23]. Participants were instructed not
to eat or drink large amounts of liquids two hour be-
fore testing, refrain from coffee and nicotine two
hours before test, and avoid intensive training the
same day and the day prior to the test. Height (cm),
weight (kg), blood pressure and heart rate at rest
were measured before testing. Participants should not
conduct the test if he or she: Ended cytostatic infu-
sion less than 24 h before the test, experienced chest
pains (or pressure), resting dyspnea, feeling faint or
dizziness of unknown source, had injuries that could
be aggravated by the test, or had a fever or infection
at the time of the test. Those participants who got
intravenously administered chemotherapy did the fol-
low up CPET earliest a week after ending treatment.
Participants were fitted and familiarized to a two-way
breathing mask and headgear (7450 Series V2; Hans
Rudolph, Inc.) before stepping on to the treadmill and
starting the test. Ventilation and gas exchange variables
were measured continuously using a breath-by-breath
gas analysis system (Uppsala; Sensor Medics, Vmax 29,
Care Fusion, San Diego, USA) or mixing chamber
(Lund and Linköping; Oxycon Pro, Erich Jaeger GmbH,
Hoechberg, Germany), which was calibrated according
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to the instructions of the manufacturer before each test.
The gas exchange variables were reported as 30 s
averages. Heart rate was measured continuously with a
heart rate sensor (Uppsala, Lund) (T34, Polar Electro
KY, Kempele, Finland) or a 12-lead ECG recording
system (Linköping) (GE Case V6.73. GE Healthcare).
The rating of perceived exertion (RPE) was recorded by
a standardized Borg-scale [25]. The test continued until
volitional exhaustion occurred or the test leader observed
indications for terminating the maximal test [26]. After
completion of the test the participants walked calmly on
the treadmill until ventilation, heart rate levels and leg
fatigue normalized. All tests were evaluated after comple-
tion and criteria consistent with an accepted V̇O2 max
where set at Borg ≥17 or RER ≥1.1.
Independent variables
Physical activity level was objectively monitored with
Sense Wear™ Mini Armband (SWA) (BodyMedia Inc.
Pittsburgh, PA, USA) according to manufacturer instruc-
tions. SWA has been shown valid compared to double
Fig. 1 Flow-chart illustrating participant flow through enrolment, baseline measurement, and follow-up in the present study. Abbreviations: MFI,
Multidimensional Fatigue Inventory-20, SWA, Sensewear Armband
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labeled water in healthy adults [27] and compared to
indirect calorimetry in both healthy adults [28] and
patients with cancer [29]. Participants were instructed to
wear the SWA for seven consecutive days, and only
remove it during water-based activities. Data from the
SWA was downloaded and analyzed with software
developed by the manufacturer (Sense Wear Professional
Research Software V.8.1, Algorithm V2.2.4).
In the present study average minutes of moderate-to-
vigorous intensity physical activity (MVPA) per day at
baseline were included. The SWA was programmed to
record PA in 1-min epochs. The cut-points defined
MVPA as ≥ 3 METs according to Garber et al. [30].
Cancer related fatigue was reported using the Multidi-
mensional Fatigue Inventory-20 (MFI) questionaire [31] at
baseline. The MFI is a validated self-report questionnaire
that has been used to assess fatigue in patients with a
variety of cancers [32]. It consists of 20 items grouped into
five subscales representing general fatigue, physical
fatigue, reduced activity, reduced motivation and mental
fatigue. The MFI has been reported to be a valid and reli-
able (average Cronbach’s alpha = 0.84) instrument for use
amongst people with cancer [31]. For the present study
we were interested in physical fatigue at baseline as it may
hinder physical activity and in turn affect V̇O2 max. Cut
point for determining physical fatigue was based on work
by Hagelin et al. [32] and Purcell et al. [33] and were set at
scores > 10.4 on the physical fatigue subscale.
Health-related data on cancer diagnosis and primary
adjuvant treatment were collected from medical records
at baseline.
Sociodemographic data on age, sex, education, work
situation, living conditions, and sick leave was collected
from study-specific questionnaires.
Statistical analysis
Descriptive characteristics are presented as mean values
with standard deviation (SD) unless otherwise stated and
results as mean with 95% confidence intervals (CI).
Between-group differences were analyzed with Wilcoxon
Signed Ranks test due to lack of assumption about normal-
ity and homogeneity of variance.
Multivariate linear regression models were applied to
assess whether age, diagnosis group, type of adjuvant treat-
ment, MVPA at baseline and physical fatigue at baseline
were associated with changes in V̇O2 max. Diagnosis group
was recoded into two categories; “breast cancer” and “pros-
tate and colorectal cancer” due to few participants in the
two latter groups. Type of adjuvant treatment was coded
into three categories; “adjuvant chemotherapy treatment”,
“radiotherapy treatment” and “endocrine therapy treat-
ment”. Physical fatigue at baseline was coded as “physical
fatigue at baseline” or “no physical fatigue at baseline”.
The final multivariate model was built as described
by Hosmer and Lemeshow [34]. This means that all
independent variables with P ≤ 0.2 in the bivariate
analysis were included in the multivariate analysis.
Adjuvant radiation therapy was included in the multi-
variate analysis despite P ≥ 0.2 because type of adjuvant
treatment was recoded into three design variables and
adjuvant chemotherapy treatment had a P ≤ 0.2. Also,
type of adjuvant treatment is known to be a clinically
important variable for V̇O2 max in breast cancer pa-
tients [8]. In the multivariate analysis the least signifi-
cant variable from the bivariate analysis was removed
in a step-wise fashion and the analyses were performed
again. This removed age and no physical fatigue. The
procedure was repeated until only significant independ-
ent variables remained. Adjuvant treatment and MVPA
were not removed from the final model.
The IBM SPSS version 22.0 statistical software pro-
gram (Statistical Product and Service Solutions, Chicago,
IL, USA) was used for all analysis. The level of signifi-
cance was set to 0.05.
Results
Table 1 shows the characteristics of the study partici-
pants at baseline stratified by V̇O2 max measurement at
both baseline and six months compared to baseline only.
Participants with and without follow up V̇O2 max
measurements were similar with respect to age,
height, weight, cohabitation, education level, working
status and diagnosis. Physical fatigue was reported by
94% of participants at baseline. There were no differ-
ences in MVPA levels between diagnosis groups at
baseline.
In linear regression analysis, fatigue, age and diagnosis
were not associated with changes in V̇O2 max during
treatment. MVPA at baseline and adjuvant treatment
explained 23% of the variability in changes in V̇O2 max
(Table 2).
A 30 min higher MVPA before start of adjuvant
treatment was associated with a 5% higher V̇O2 max
(P = 0.010) at six months follow up when adjusted for
adjuvant treatment (Table 2). Adjuvant chemotherapy
treatment was associated with a reduction in V̇O2 max
(P = 0.028). Patients receiving adjuvant chemotherapy
treatment had a mean decline in V̇O2 max of 10% (− 19,
− 1.1, 95% CI) compared to patients receiving adjuvant
endocrine therapy treatment only. Adjuvant radiotherapy
and endocrine therapy were not associated with changes
in V̇O2 max:
Table 3 shows average V̇O2 max , peak V̇ E, HR, RER
and RPE from the maximal exercise test at baseline and
six months after start of adjuvant treatment for the dif-
ferent treatment groups. There was a significant increase
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(P = 0.031) in RPE peak from before treatment to six
month follow up, from 16.6 to 17.2, respectively in the
radiotherapy group. There were no significant changes
in V̇O2 max, V̇ E peak, RER peak, or HR peak.
Discussion
The results of the present study provide knowledge about
clinically relevant correlates to subsequent changes in
cardiorespiratory fitness in patients with cancer during
Table 1 Baseline characteristics of participating subjects with (n = 55) and without (n = 30) maximal oxygen uptake measurements
before and six months after start of adjuvant cancer treatment. Results are presented as frequencies and percentages in parenthesis
unless otherwise stated*
Baseline and follow up n = 55 (64.7) Baseline only n = 30 (35.3)
Age yrs., mean (SD) 58.8 (11.1) 59.2 (12.9)
Height cm, mean (SD) 168 (7.7) 167 (5.6)a
Weight kg, mean (SD) 74.3 (14) 75.2 (16)a
Females, n (%) 42 (80.8)b 27 (90)
Cohabitation b
Married/cohabitant, n (%) 42 (80.8) 21 (70)
One couple, two households, n (%) 3 (5.8) 3 (10)
Living alone, n (%) 7 (13.5) 6 (20)
Education level, n (%) c
Compulsory school, n (%) 4 (7.8) 4 (13.3)
High School, n (%) 17 (33.3) 8 (26.7)
College/university n (%) 30 (58.8) 18 (60)
Working status b
Full time work, n (%) 15 (28.8) 6 (20)
Part time work, n (%) 6 (11.5) 3 (10)
Retired, Homemaker n (%) 20 (38.5) 12 (40)
Sick leave, n (%) 11 (21.2) 9 (30)
Diagnosis
Breast cancer, n (%) 45 (81.8) 26 (86.7)
Prostate cancer, n (%) 8 (14.5) 2 (6.7)
Colorectal cancer, n (%) 2 (3.6) 2 (6.7)
Primary adjuvant treatment
Chemotherapy, n (%) 20 (36.4) 14 (46.7)
Type chemotherapyd
Docetaxcel + FEC low-dose 9 (45.0)
Docetaxcel + FEC high-dose 8 (40.0)
CAPOX 1 (5.0)
Capecitabine single 1 (5.0)
Radiation therapy, n (%) 18 (32.7) 10 (33.3)
Endocrine treatment, n (%) 17 (30.9) 6 (20)
Physical fatigue, n (%) 47 (94)e 28 (93.3)
MVPA (SD)* (min.day−1) 47.6 (30.1)f 33.3 (19.5)g
Abbreviations: Docetaxcel, breast cancer only, low-dose 75–80 mg/m2, high-dose 90–100 mg/m2. FEC, breast cancer only, low to high-dose, fluorouracil 500–600
mg/m2 and/or only Epirubicin 75–100 mg/m2 and cyclophosphamide 500–600 mg/m2. CAPOX, colorectal only, Capecitabine and Oxaliplatin. Capecitabine single,
colorectal only. MVPA, moderate and vigorous physical activity
a Missing = 5
b Missing = 3
c Missing = 4
d Missing = 1, % of n participants receiving chemotherapy
e Missing = 5
f Missing = 7
g Missing = 24
Wiestad et al. BMC Sports Science, Medicine and Rehabilitation           (2020) 12:53 Page 6 of 10
adjuvant treatment. Findings indicate that adjuvant
chemotherapy treatment is associated with a 10% decline in
V̇O2 max six months after start of treatment. The results
also indicate that time spent in MVPA before start of adju-
vant treatment is associated with higher levels of V̇O2 max
six months later. Fatigue, age and diagnosis were not asso-
ciated with changes in V̇O2 max during treatment.
Our results are in line with the work of several other
studies examining the association between cancer
treatment and cardiorespiratory fitness [5, 8, 35, 36]. In
a recent meta-analysis including 26 clinical trials and ob-
servational studies that measured V̇O2 max pre- or post-
adjuvant therapy, it was shown that CRF in patients with
breast cancer decreased with approximately 10% during
cancer treatment and that reduced CRF can be mea-
sured seven years after end of chemotherapy treatment
[7]. In the study by Peel et al. [7], where 78% of the
women were treated with adjuvant chemotherapy,
patients with breast cancer had a 17% lower weighted
mean V̇O2 max prior to adjuvant treatment and a 25%
lower V̇O2 max after completion of adjuvant therapy
compared to healthy sedentary women [7]. In the
present study, women treated with adjuvant chemother-
apy had a similar V̇O2 max prior to adjuvant treatment
as healthy age matched women (30.4 ml kg− 1 . min− 1)
[37], but a 8.5% lower V̇O2 max (27.9 (ml kg
− 1 . min− 1)
six months after start of adjuvant chemotherapy treat-
ment compared to healthy age matched women. Our
Table 2 Regression summaries for multivariate analysis with the dependent variable % change in VO2max from before treatment to
six months follow up. The coefficients are given with 95% confidence intervals
Step-wise multivariate analysis Final multivariate analysis
Coefficients P-values Coefficients P-values
Breast cancer 8.829 (−4.085, 21.743) 0.174
Adjuvant chemotherapy treatment* −8.591 (− 18.959, 1.778) 0.102 − 10.066 (− 19.000, − 1.131) 0.028
Adjuvant radiation therapy treatment * −1.116 (− 12.426, 10.194) 0.843 −3.490 (− 12.870, 5.890) 0.457
MVPA at baseline (min.day− 1) 0.182 (0.036, 0.327) 0.016 0.167 (0.042, 0.291) 0.010
Age (yrs) 0.075 (−0.473, 0.623) 0.783
No physical fatigue at baseline 3.098 (−17.323, 23.519) 0.760
Abbreviations: MVPA; Moderate- to-vigorous physical activity; VO2max; maximal oxygen uptake
*Compared to endocrine therapy treatment
Table 3 Data from the exercise test of the study participants who completed baseline and follow up testing (n = 55) presented by
before treatment and after six month follow up, stratified by treatment group. Data are given as mean with confidence intervals (CI)
and standard deviation (SD) in parentheses unless otherwise stated*
Before treatment
mean (SD)
95% CI Six month follow
up mean (SD)
95% CI P-valueb
Chemotherapy (N = 20) VO2max (ml kg−1. min− 1) 31 (7.1) 27.6–34.3 28.7 (6.2) 25.8–31.6 .191
VE peak (L min− 1) 84 (15.4) 76.8–91.2 82.4 (19.4) 73.3–91.5 .296
RER peak 1.25 (0.1) 1.22–1.29 1.22 (0.1) 1.17–1.27 .147
RPE peak 17.2 (1.2) 16.6–17.8 17.8 (1.2) 17.2–18.3 .058
HR peak (beats. min−1) 173 (13) 166.5–178.6 170 (11.1) 164.3–174.6 .054
Radiotherapy (N = 18) VO2max (ml kg−1. min− 1) 29.4 (6.7) 26.1–32.7 29.4 (7.9) 25.5–33.3 .794
VE peak (L min− 1) 77.8 (18.7) 68.5–87.1 73.5 (28.2) 59.4–87.5 .845
RER peak 1.20 (0.1) 1.15–1.25 1.17 (0.1) 1.12–1.23 .140
RPE peak 16.6 (1.3) 15.9–17.2 17.2 (1.5) 16.4–17.9 .031*
HR peak (beats. min−1) 169 (20.4) 158.6–178.9 165 (16.4) 156.7–173 .138
Endocrine therapy (N = 17) VO2max (ml kg− 1. min− 1) 32 (6.8) 28.5–35.5 33.1 (9.2) 28.4–37.8 .162
VE peak (L min− 1) 86.6 (18.6) 77.1–96.2 83.7 (17.2) 74.8–92.5 .113
RER peak 1.23 (0.1) 1.16–1.30 1.19 (0.1) 1.13–1.24 .162
RPE peak 17.4 (1.2) 16.8–18 17.2 (1.7) 16.3–18.1 .558
HR peak (beats. min−1) 166 (17.8) 156.9–175.2 166 (19.7) 156.2–176.4 .816
a Abbreviations: VO2max, highest recorded oxygen uptake during exercise test; VE peak, highest recorded ventilation; RER peak, highest recorded respiratory
exchange ratio; RPE peak, highest reported perceived exertion; HR peak, highest recorded heart rate; MVPA, Moderate and vigorous physical activity
b P-values for any differences between groups
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patients had a higher V̇O2 max in both the pre- and
post-adjuvant setting compared to the patients in the
study by Peel et al. [7], which could be due to differences
in testing protocol (treadmill vs. bicycle), but the relative
decline of 10% was similar.
The reason for the decline in V̇O2 max in patients
treated with adjuvant chemotherapy is likely multifactor-
ial, involving multiple organ components of the oxygen
transport chain [7]. Many of these negative effects of
chemotherapy are dose dependent, but although treat-
ment regimens are focusing on reducing doses of
chemotherapy, there are still several aspects which could
reduce V̇O2 max both directly and indirectly, through
reduced physical activity levels. Chemotherapy used in
breast cancer treatment are associated with both short-
and long term cardiac complications, and anthracycline-
based adjuvant therapy and treatment with trastuzumab
in particular, carries a substantial long term risk of heart
failure [4, 36]. Unfavorable alterations in myocardial tis-
sue due to chemotherapy treatment results in reduced
left ventricular ejection fraction which in turn reduces
convective oxygen delivery [13]. Also, anthracycline-
caused cytotoxic damage leads to compensatory alter-
ations in autonomic tone, which may have implications
for the heart rate reserve (HRR) and CRF [38]. However,
we did not see any unfavorable changes in heart rate in
our patients. Except for the radiotherapy group, all pa-
tients reported consistent RPE at both pre- and posttest
indicating the same amount of effort. Furthermore,
studies have reported negative effects of chemotherapy
directly to skeletal muscle [39, 40]. In these studies, both
the force-generating abilities and mitochondrial function
are affected negatively and the decrease is dependent
upon the length of chemotherapy exposure [39, 40].
It has previously been reported that patients reduce
their PA levels prior to adjuvant treatment [22], and that
V̇O2 max in cancer patients are already lower prior to
adjuvant treatment compared to healthy age matched
controls [7]. Our patients had a mean MVPA of 47.6
(30.1) min.day− 1 prior to adjuvant treatment, which is
above the minimum recommended 150 min of moderate
intensity PA per week [17]. However, mean MVPA var-
ied among the participants. We observed that those with
mean MVPA less than 30 min per day before start of
adjuvant treatment had a lower mean V̇O2 max both
prior and after treatment compared to those with mean
MVPA > 30min (results not shown). The group with <
30min MVPA per day were also the only group with a
significant decline in V̇O2 max from before start of
treatment to six months after. A study on PA among
German patients with breast cancer found that PA levels
decreased significantly during adjuvant therapy, and the
decline was stronger in patients treated with chemo-
and/or radiotherapy compared to endocrine or no
adjuvant therapy [16]. This corresponds to our findings
were adjuvant chemotherapy were associated with a
decline in V̇O2 max, possibly due to a reduced PA level
in addition to the possible cardiac and direct muscular
complications. Alternatively, our results might indicate
that a minimum threshold of MVPA before and during
treatment can protect against some of the side effects
normally observed with adjuvant chemotherapy.
There is evidence that physical activity, even high
intensity exercise, is both feasible and safe for
patients with cancer both during and after adjuvant
treatment [17, 18]. Patients with cancer participating
in exercise programs may increase or maintain their
CRF [18], and also, there is evidence that exercise
can protect against the acute cardiotoxic effect of
anthracyclines and in turn, reduced convective oxy-
gen delivery [41]. Our findings suggest that it could
be beneficial to take measures to promote PA to
patients with cancer before start of oncological treat-
ment to prevent a decrease in PA level, and conse-
quently a reduced V̇O2 max. Studies have shown that
an oncologist recommendation [42] and physical ac-
tivity facilities in connection with the hospital [43],
might be of importance to increase exercise behavior
in newly diagnosed patients.
The present study had a number of strengths, in-
cluding the inclusion of patients with different cancer
diagnosis and type of treatment, the objective
measurements of physical activity and direct and
maximal testing of cardiorespiratory fitness before
start of adjuvant treatment. To our knowledge, few
studies have included measured V̇O2 max in patients
with different cancer diagnosis before start of adju-
vant therapy [44].
The present study also had several limitations that
should be noted. Less than 50% of the eligible patients
completed the study. There was a larger proportion of
women and patients with breast cancer among the in-
cluded patients, and results should be interpreted with
caution for patients with colorectal or prostate cancer.
Although we did our best to recruit patients with pros-
tate cancer and colorectal cancer, we experienced sig-
nificant problems in recruiting the two latter groups.
Despite the overrepresentation of patients with breast
cancer, the distribution between the different cancer
therapies (chemotherapy, radiotherapy and endocrine
therapy) was evenly distributed, with around 30% in
each treatment group. Our sample consists of patients
who are sufficiently fit to participate in such a study,
and might be more active than the average patient
group resulting in higher V̇O2 max values [45]. How-
ever, in case of such a bias, real PA and CRF in the
overall population of patients with cancer may be even
lower than in our study.
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Conclusion
Adjuvant chemotherapy was associated with a 10% re-
duction in V̇O2 max during treatment whereas higher
levels of MVPA before start of adjuvant treatment were
positively associated with a higher V̇O2 max after end of
adjuvant treatment. As there was a larger proportion of
women with breast cancer among the included patients,
we cannot generalize these results to all cancer popula-
tions. However, these results combined with previous
findings of impaired V̇O2 max among patients with
cancer [46–49], emphasize the clinical importance of in-
creasing or maintaining V̇O2 max in this phase of cancer
treatment, and highlight the importance of physical ac-
tivity on cardiorespiratory fitness in patients with cancer.
Future studies should address increasing PA in the early
phase of treatment and further examine the association
between PA and V̇O2 max; and in particular the under-
lying mechanisms.
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